Health
Combination immunotherapy benefits subset of patients with advanced prostate cancer. – Brinkwire
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC), an “immune-cold” cancer that does not typically respond well to immunotherapy.
In a cohort of patients without previous chemotherapy treatment, the overall response rate (ORR) was 25% and median ove…
-
Noosa News9 hours agoArnie the dog found dead in stolen ute after week of searching
-
Noosa News8 hours ago‘Beyond devastated’ Brisbane family learn missing German shepherd Arnie found dead in back of stolen car
-
Noosa News14 hours agoTeenage girl dies in hit-and-run, police hunt for ute
-
Noosa News15 hours agoTeenage girl killed in alleged hit-and-run at Margate north of Brisbane